Elevai Labs Inc. financial data

Symbol
ELAB on Nasdaq
Industry
Pharmaceutical Preparations
Location
120 Newport Center Drive, Ste 250, Newport Beach, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Reactive Medical Labs Inc. (to 10/14/2021)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 78.1 %
Quick Ratio 30.4 %
Debt-to-equity -4.71 %
Return On Equity 12.3 %
Return On Assets -1.19 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.2M shares
Common Stock, Shares, Outstanding 18.9M shares
Common Stock, Value, Issued 1.89K USD
Weighted Average Number of Shares Outstanding, Basic 18.3M shares +83.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.47M USD +91.3%
Cost of Revenue 166K USD +53.7%
Research and Development Expense 364K USD -60.8%
Selling and Marketing Expense 1.56M USD +533%
General and Administrative Expense 2.91M USD +25.3%
Operating Income (Loss) -1.41M USD -33.7%
Net Income (Loss) Attributable to Parent -4.75M USD -10.4%
Earnings Per Share, Basic -0.32 USD/shares +39.1%
Earnings Per Share, Diluted -0.32 USD/shares +39.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Inventory, Net 979K USD
Assets, Current 2.03M USD
Property, Plant and Equipment, Net 55.8K USD
Operating Lease, Right-of-Use Asset 138K USD
Intangible Assets, Net (Excluding Goodwill) 2.85M USD
Assets 5.08M USD
Accounts Payable, Current 1.14M USD
Accrued Liabilities, Current 40.8K USD
Liabilities, Current 1.94M USD
Operating Lease, Liability, Noncurrent 26.6K USD
Liabilities 2.44M USD
Common Stocks, Including Additional Paid in Capital 493K USD +67.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.24K USD
Retained Earnings (Accumulated Deficit) -9.83M USD
Stockholders' Equity Attributable to Parent 2.64M USD +3823%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.83M USD
Liabilities and Equity 5.08M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.32M USD -162%
Net Cash Provided by (Used in) Investing Activities -59.2K USD -429%
Common Stock, Shares Authorized 300M shares
Common Stock, Shares, Issued 18.9M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.38M USD -2085%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 100K USD -83.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.54K USD +72.3%
Operating Lease, Liability 140K USD
Depreciation 21.2K USD +628%
Payments to Acquire Property, Plant, and Equipment 9.16K USD -18.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.75M USD -10.4%
Lessee, Operating Lease, Liability, to be Paid 148K USD
Property, Plant and Equipment, Gross 82K USD
Operating Lease, Liability, Current 140K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 67.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 67.4K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.18K USD
Deferred Tax Assets, Operating Loss Carryforwards 1.71M USD +158%
Preferred Stock, Shares Authorized 75M shares 0%
Additional Paid in Capital 10.8M USD +182%
Share-based Payment Arrangement, Expense 55.3K USD -26.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%